Twist Bioscience CFO Laponis disposes of $384,822 in shares

Adam Laponis, the Chief Financial Officer of Twist Bioscience Corp (TWST), sold 2,462 shares of the company's common stock on October 9, 2026. The shares were sold at $156.3049 each, resulting in a total of $384,822. This transaction occurred as the stock price had dropped approximately 9% over the past week, reaching $151.33, despite a significant year-over-year increase of 404%.

According to InvestingPro analysis, the stock is currently considered overvalued relative to its estimated fair value. The shares were not sold at Laponis' discretion; they were part of a required transaction to cover tax withholding obligations associated with the vesting of restricted stock units under Twist Bioscience's equity incentive plans.

Following this sale, Laponis now owns 98,114 shares of Twist Bioscience common stock directly. Twist Bioscience has been involved in several noteworthy developments recently. The company partnered with Eli Lilly’s TuneLab to provide antibody characterization data services utilizing AI and machine learning models aimed at advancing biotech innovation.

Additionally, Twist Bioscience filed a prospectus supplement to register the resale of shares issued to Invenra Inc., as per the terms of their Stock Purchase Agreement under the Registration Rights Agreement. Analysts have offered varying opinions on Twist Bioscience's market position and future potential. Jefferies initiated coverage with a Hold rating and a $150.00 price target, BWS Financial started coverage with a Sell rating and a $45.00 price target, while Guggenheim reiterated a Buy rating with a $107.00 price target, citing potential in AI drug discovery.

These contrasting analyst perspectives underscore the diverse viewpoints on Twist Bioscience's market outlook and prospects.